Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...

The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

Health plans will need to navigate a difficult financial environment caused by increased healthcare costs and potential ...

Fianlimab plus Libtayo demonstrated persistent and significant clinical activity in patients with advanced melanoma.

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions ...

A small study of 18 patients with skin cancer found that the combination of vitamin D and chemotherapy provided an immune ...

Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these ...

Predictions for this year from Perry Cohen, Pharm.D., CEO of the TPG Family of Companies and Managed Healthcare Executive ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Blue Shield of California new CEO Lois Quam said she will focus on the challenges that members face with accessing healthcare ...